PITTSBURGH--(BUSINESS WIRE)--In Vitro Chemoresponse Assessment of Optimally and Sub-Optimally Debulked Primary Ovarian Cancer, a study submitted by Dr. Jill Whyte and presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS) on October 13, 2012 in Vancouver, compares ChemoFx® results in optimally and sub-optimally debulked primary ovarian cancer patients to determine whether in vitro chemoresponse differs between these patient sets.
The percentage of specimens which ChemoFx deemed non-responsive to all drugs tested significantly differed according to debulking status, and there was also a statistically significant difference in the percentage of responsive specimens according to debulking status for the carboplatin/docetaxel drug combination. Comparisons for other platinum and/or taxane-based drug combinations also trended towards significance. These results suggest that the inherent biology of sub-optimally debulked tumors may contribute to increased chemoresistance and poorer patient prognosis. Personalized medicine tools such as ChemoFx may have increased utility in refining and personalizing treatment for these poor prognosis patients.
“This study answers a clinical question of high interest in the gynecologic oncology community,” says Dr. Whyte, lead author of the study. “ChemoFx made it possible to observe possible biological differences that exist between these two populations, which may ultimately help with treatment decisions.”
About Precision Therapeutics
Precision Therapeutics, a
leading life-science company based in Pittsburgh, Pennsylvania, is
dedicated to personalized cancer care. Precision offers a portfolio of
products developed to help guide physicians and patients with difficult
clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated, straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, approximately 80,000 patient specimens have been submitted for ChemoFx® testing using 105 unique chemotherapy treatments and combinations.
For more information, visit: www.precisiontherapeutics.com or www.chemofx.com